No Data
CSTONE PHARMA-B (02616) announced that the GEMSTONE-303 study data for Shuglibo (Zejimei) was published in JAMA.
CSTONE PHARMA-B (02616) announced the results of the study on Suglirumab (Zejulam) GEMSTONE-303...
Hong Kong stocks movement | CSTONE PHARMA-B (02616) rises over 6% again as the drug Shuglik has recently been included in the European Society for Medical Oncology guidelines.
CSTONE PHARMA-B (02616) surged over 6% again, as of the time of writing, up 5.81%, priced at 3.28 Hong Kong dollars, with a trading volume of 19.5728 million Hong Kong dollars.
AI empowers the research and development of Innovative Drugs, and Basilea Pharmaceuticals (02616) enjoys the benefits of being a pioneer.
Since January 15 of this year, the stock price of CStone Pharmaceuticals (02616) has been continuously rising. As of the closing on February 18, the maximum increase in the Range reached 41.58%, and during this period, it hit a new high for the stock price in nearly 13 months. This performance is not only attributed to the market's revaluation of this leading Innovative Drugs company, but also related to its first-mover advantage in the AI pharmaceutical sector.
Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 28% Jump Looks Justified
Insiders Of CStone Pharmaceuticals Reap Rewards After Their Investment Jumps Another CN¥13m
CStone Pharmaceuticals' Lung Cancer Drug Included in ESMO Living Guideline
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
